<DOC>
	<DOCNO>NCT00869791</DOCNO>
	<brief_summary>This study evaluate pharmacokinetics , motor effect , assess safety IPX066 compare immediate-release cabridopa-levodopa formulation subject advance Parkinson 's disease .</brief_summary>
	<brief_title>A Study Compare Pharmacokinetics Pharmacodynamics IPX066 Standard Carbidopa-Levodopa</brief_title>
	<detailed_description>This randomize , multicenter , open-label , single multiple oral dose , two-treatment , two-period , crossover study LD-experienced subject Parkinson 's disease ( PD ) . Subjects received 7 day one treatment ( IPX066 IR CD-LD ) follow approximate 7-day washout period follow another 7 day treatment ( IR CD-LD IPX066 ) . During approximate 7-day washout period , subject take prestudy CD-LD regimen . Pharmacokinetic efficacy/pharmacodynamic measurement do Days 1 8 . Safety measure ( electrocardiogram [ ECGs ] , clinical laboratory test , vital sign , adverse event [ AEs ] , concomitant medication ) evaluate course study .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>1 . Male female diagnose idiopathic PD , without know cause Parkinsonism . 2 . If female childbearing potential , subject abstinent continue practice willing continue throughout study appropriate contraceptive ( define Nova ring , oral , injected , transdermal patch , implant , barrier ) . The subject must agree take every precaution ensure pregnancy occur study . 3 . At least 30 year old time diagnosis PD . 4 . Mini Mental State Examination ( MMSE ) â‰¥ 26 Screening Visit . 5 . A responder LD currently chronically treat stable dosage commercially available standard , orally disintegrate , controlledrelease CD LD least 1 month . 6 . Must predictable fluctuation `` '' `` '' state . 7 . Hoehn Yahr Stage IIV `` '' . 8 . Able provide inform consent willing sign Health Insurance Portability Accountability Act ( HIPAA ) authorization . 9 . Able willing comply protocol , include availability schedule study visit blood sample collection . 1 . Pregnant breastfeeding . 2 . Diagnosed atypical parkinsonism . 3 . History , physical finding laboratory result suggest diagnosis PD . 4 . Allergic nonresponsive previous CDLD therapy . 5 . Any medical ( e.g. , liver kidney impairment , peptic ulcer ) condition/history , Investigator 's opinion , may jeopardize subject 's safety . 6 . Exposure investigational agent within 30 day prior Visit 1 . 7 . Donated blood plasma within 28 day . 8 . Had prior functional neurosurgical treatment PD ( ablation Deep Brain Stimulation ) .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Parkinson 's</keyword>
</DOC>